945467-33-4Relevant academic research and scientific papers
Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor
Morriello, Gregori J.,Chicchi, Gary,Johnson, Tricia,Mills, Sander G.,Demartino, Julie,Kurtz, Marc,Tsao,Zheng, Song,Tong, Xinchun,Carlson, Emma,Townson, Karen,Wheeldon, Alan,Boyce, Susan,Collinson, Neil,Rupniak, Nadia,Devita, Robert J.
supporting information; experimental part, p. 5925 - 5932 (2010/11/18)
Previously, we had disclosed a novel class of hNK1 antagonists based on the 5,5-fused pyrrolidine core. These compounds displayed subnanomolar hNK1 affinity along with good efficacy in a gerbil foot-tapping (GFT) model, but unfortunately they had low to moderate functional antagonist (IP-1) activity. To elaborate on the SAR of this class of hNK1 compounds and to improve functional activity, we have designed and synthesized a new class of hNK1 antagonist with a third fused ring. Compared to the 5,5-fused pyrrolidine class, these 5,5,5-fused tricyclic hNK1 antagonists maintain subnanomolar hNK1 binding affinity with highly improved functional IP-1 activity (1 binding affinity, off-target selectivity, pharmacokinetic profile and in vivo activity. Complete inhibition of agonist activity was observed at both 0 and 24 h in the gerbil foot-tapping model with an ID50 of 0.02 mpk at both 0 and 24 h, respectively.
Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists
Morriello, Gregori J.,DeVita, Robert J.,Mills, Sander G.,Young, Jonathan R.,Lin, Peter,Doss, George,Chicchi, Gary G.,DeMartino, Julie,Kurtz, Marc M.,Tsao, Kwei-Lan C.,Carlson, Emma,Townson, Karen,Wheeldon, Alan,Boyce, Susan,Collinson, Neil,Rupniak, Nadia,Moore, Stephen
, p. 2156 - 2170 (2008/12/21)
Previous work on human NK1 antagonists in which the core of the structure is a substituted pyrrolidine has been disclosed. These compounds showed good binding affinity and functional IP activity, however, many did not exhibit the necessary brai
HEXAHYDRO-3H-PYRROLIZIN-3-ONES USEFUL AS TACHYKININ RECEPTOR ANTAGONISTS
-
Page/Page column 31, (2008/06/13)
The present invention is directed to certain hexahydroyrrolidinone compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
